INVA: Innoviva, Inc.
About
Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
Current Value
$19.091 Year Return
Current Value
$19.091 Year Return
Key Details
Market Cap
$1.20B
P/E Ratio
27.76
1Y Stock Return
42.14%
1Y Revenue Growth
20.48%
Dividend Yield
0.00%
Price to Book
1.8
Strategies that include INVA
Stock's related to INVA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DOX | 42.52% | $9.47B | -0.74% | 2.26% |
| CLDT | 42.18% | $425.53M | -12.03% | 3.24% |
| LMND | 41.44% | $2.87B | +150.56% | 0.00% |
| QCRH | 41.05% | $1.51B | +75.87% | 0.27% |
| UVSP | 41.01% | $891.91M | +64.40% | 2.76% |
| ACRE | 40.99% | $388.89M | -28.20% | 15.31% |
| BHLB | 40.72% | $1.29B | +44.14% | 2.40% |
| OLP | 40.43% | $617.02M | +46.60% | 6.26% |
| RCKY | 39.73% | $155.86M | -17.74% | 2.95% |
| KREF | 39.73% | $796.38M | -5.46% | 10.31% |
| YORW | 39.66% | $514.17M | -3.87% | 2.37% |
| BY | 39.40% | $1.36B | +51.33% | 1.18% |
| PFC | 39.35% | $990.65M | +38.69% | 4.50% |
| JAKK | 39.27% | $303.66M | -7.19% | 0.00% |
| KFRC | 39.20% | $1.10B | -8.71% | 0.66% |
| KTOS | 38.96% | $3.78B | +33.46% | 0.00% |
| MFA | 38.95% | $1.13B | +5.15% | 12.73% |
| TRST | 38.85% | $691.41M | +34.26% | 3.98% |
| NMFC | 38.76% | - | - | 11.01% |
| PFLT | 38.61% | - | - | 11.07% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PLG | -<0.01% | $173.19M | +67.33% | 0.00% |
| CBOE | -0.06% | $21.46B | +15.84% | 1.11% |
| ATEC | 0.07% | $1.36B | -16.49% | 0.00% |
| WRAP | -0.16% | $62.86M | -49.45% | 0.00% |
| HPK | 0.17% | $1.86B | -9.44% | 0.81% |
| BACK | -0.20% | $1.76M | -32.90% | 0.00% |
| BNED | -0.22% | $277.22M | -91.94% | 0.00% |
| CRVO | 0.24% | $83.20M | +2.86% | 0.00% |
| GTE | -0.24% | $225.69M | -1.28% | 0.00% |
| RNR | -0.33% | $13.74B | +23.09% | 0.58% |
| NNE | 0.38% | $833.66M | +531.50% | 0.00% |
| KSPI | -0.48% | $20.86B | +18.06% | 3.37% |
| MASI | 0.53% | $8.75B | +73.22% | 0.00% |
| TCTM | -0.53% | $8.10M | -42.99% | 0.00% |
| MESO | -0.56% | $1.23B | +347.11% | 0.00% |
| NEXA | 0.57% | $1.02B | +30.44% | 0.00% |
| BTCT | -0.61% | $42.61M | +353.33% | 0.00% |
| POWL | 0.67% | $3.74B | +275.35% | 0.29% |
| GPCR | -0.67% | $1.88B | -36.14% | 0.00% |
| VNET | -0.69% | $954.90M | +33.82% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PULM | -13.27% | $19.83M | +202.98% | 0.00% |
| CFLT | -12.58% | $9.28B | +49.05% | 0.00% |
| HUSA | -11.26% | $16.69M | -11.56% | 0.00% |
| STG | -8.50% | $35.67M | +7.92% | 0.00% |
| FATBB | -8.48% | $81.94M | -12.91% | 11.69% |
| RELY | -7.38% | $3.96B | -7.42% | 0.00% |
| BEST | -7.16% | $31.65M | +3.88% | 0.00% |
| ARLP | -6.88% | $3.54B | +26.77% | 10.11% |
| FIVE | -6.15% | $4.65B | -54.68% | 0.00% |
| VIRT | -6.07% | $3.17B | +110.38% | 2.60% |
| NLOP | -5.75% | $458.04M | +94.60% | 0.00% |
| SUZ | -5.73% | $13.00B | -2.96% | 2.27% |
| UUU | -5.67% | $4.97M | -41.89% | 0.00% |
| ROOT | -5.10% | $1.53B | +972.93% | 0.00% |
| HIHO | -4.71% | $8.63M | 0.00% | 6.12% |
| MAGN | -4.64% | $638.97M | -3.42% | 0.00% |
| TPL | -4.52% | $32.63B | +163.13% | 0.64% |
| XOS | -4.45% | $30.51M | -57.24% | 0.00% |
| DXCM | -4.40% | $29.25B | -31.28% | 0.00% |
| VST | -4.08% | $52.69B | +349.00% | 0.56% |
ETF's related to INVA
News
SeekingAlpha
November dashboard shows the healthcare sector is overvalued by 18% relative to 11-yr averages; pharma/biotech and healthcare equipment, the most overpriced.
Yahoo
BURLINGAME, Calif., November 12, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in a fireside chat at the UBS Global Healthcare Conference in Ranch Palos Verdes, CA on Wednesday, November 13, 2024 at
Yahoo
Innoviva ( NASDAQ:INVA ) Third Quarter 2024 Results Key Financial Results Revenue: US$89.5m (up 33% from 3Q 2023). Net...
Yahoo
BURLINGAME, Calif. AP) — Innoviva Inc. INVA) on Wednesday reported earnings of $1.2 million in its third quarter.
Yahoo
BURLINGAME, Calif., November 06, 2024--Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today reported financial results for the third quarter ended September 30, 2024, and highlighted select corporate achievements.
Finnhub
Waltham - Innoviva Specialty Therapeutics, Inc., a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.